Literature DB >> 31361209

Breast MRI: State of the Art.

Ritse M Mann1, Nariya Cho1, Linda Moy1.   

Abstract

MRI of the breast has the highest sensitivity for breast cancer detection among current clinical imaging modalities and is indispensable for breast imaging practice. While the basis of breast MRI consists of T1-weighted contrast-enhanced imaging, T2-weighted, ultrafast, and diffusion-weighted imaging may be used to improve lesion characterization. Such multiparametric assessment of breast lesions allows for excellent discrimination between benign and malignant breast lesions. Indications for breast MRI are expanding. In preoperative staging, multiple studies confirm the superiority of MRI to other imaging modalities for tumor size estimation and detection of additional tumor foci in the ipsilateral and contralateral breast. Ongoing studies show that in experienced hands this can be used to improve breast cancer surgery, although there is no evidence of improved long-term outcomes. Screening indications are likewise growing as evidence is accumulating that OncologicRI depicts cancers at an earlier stage than mammography in all women. To manage the associated costs for screening, the use of abbreviated protocols may be beneficial. In patients treated with neoadjuvant chemotherapy, MRI is used to document response. It is essential to realize that oncologic and surgical response are different, and evaluation should be adapted to the underlying question. © RSNA, 2019.

Entities:  

Year:  2019        PMID: 31361209     DOI: 10.1148/radiol.2019182947

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  80 in total

Review 1.  Novel imaging approaches to screen for breast cancer: Recent advances and future prospects.

Authors:  Christopher L Vaughan
Journal:  Med Eng Phys       Date:  2019-10       Impact factor: 2.242

2.  Breast cancer screening: in the era of personalized medicine, age is just a number.

Authors:  Andrea Cozzi; Simone Schiaffino; Paolo Giorgi Rossi; Francesco Sardanelli
Journal:  Quant Imaging Med Surg       Date:  2020-12

Review 3.  Deep learning in breast radiology: current progress and future directions.

Authors:  William C Ou; Dogan Polat; Basak E Dogan
Journal:  Eur Radiol       Date:  2021-01-15       Impact factor: 5.315

4.  Radiomic analysis of HTR-DCE MR sequences improves diagnostic performance compared to BI-RADS analysis of breast MR lesions.

Authors:  Saskia Vande Perre; Loïc Duron; Audrey Milon; Asma Bekhouche; Daniel Balvay; Francois H Cornelis; Laure Fournier; Isabelle Thomassin-Naggara
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

Review 5.  Abbreviated MR Imaging for Breast Cancer.

Authors:  Laura Heacock; Alana A Lewin; Hildegard K Toth; Linda Moy; Beatriu Reig
Journal:  Radiol Clin North Am       Date:  2020-11-02       Impact factor: 2.303

6.  The emerging role of contrast-enhanced mammography.

Authors:  Andrea Cozzi; Simone Schiaffino; Francesco Sardanelli
Journal:  Quant Imaging Med Surg       Date:  2019-12

7.  Intravenous Line Phase-Wrap Artifact at Bilateral Axial 3-T Breast MRI: Identification, Analysis, and Solution.

Authors:  Einat Slonimsky; Yusef Azraq; John M Gomori; Susan Fisch; Tal Arazi Kleinman; Tamar Sella
Journal:  Radiol Imaging Cancer       Date:  2020-11-06

8.  MRI-guided core needle biopsy of the breast: Radiology-pathology correlation and impact on clinical management.

Authors:  Amy J Lilly; Meredith Johnson; Cherie M Kuzmiak; David W Ollila; Siobhan M O'Connor; Johann D Hertel; Benjamin C Calhoun
Journal:  Ann Diagn Pathol       Date:  2020-07-03       Impact factor: 2.090

9.  Radiomics methodology for breast cancer diagnosis using multiparametric magnetic resonance imaging.

Authors:  Qiyuan Hu; Heather M Whitney; Maryellen L Giger
Journal:  J Med Imaging (Bellingham)       Date:  2020-08-24

10.  Forewarned Is Forearmed: Can Better Patient Counseling Increase MRI Utilization in High-Risk Women?

Authors:  Amy E Cyr; Ranjna Sharma
Journal:  Ann Surg Oncol       Date:  2020-08-09       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.